3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
2
Recurrence
2
Melanoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Interventions
Cyclophosphamide
48
fludarabine phosphate
28
Filgrastim
27
Radiotherapy
26
Antilymphocyte Serum
26
Busulfan
24
Cyclosporine
23
Peripheral Blood Stem Cell Transplantation
19
Mycophenolic Acid
18
Cord Blood Stem Cell Transplantation
17
Methylprednisolone
16
Methotrexate
16
Melphalan
15
Etoposide
15
Tacrolimus
12
Whole-Body Irradiation
11
Cytarabine
9
Thiotepa
6
Vincristine
5
Psychiatric Rehabilitation
5
sargramostim
4
aldesleukin
4
Sirolimus
4
Leucovorin
4
Granulocyte Colony-Stimulating Factor
4
fludarabine
3
Prednisone
3
Early Intervention, Educational
3
Daunorubicin
3
glucarpidase
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
bempegaldesleukin
×
Sarcoma
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts